Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diva LaboratoriesROCO:4153 -1.88%74 Median PS Value is NT$34.96 as of Jul. 15, 2026, which is 100% below its 10-year median of 1.08. GuruFocus rates ROCO:4153 with a GF Score™ of 74/100 and a GF Value™ of NT$38.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 88 Medical Diagnostics & Research companies, Diva Laboratories ranks worse than 51.14% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Diva Laboratories's Median PS Value or its related term are showing as below:
ROCO:4153'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.89 Med: 1.08 Max: 1.12
Current: 0.89
During the past 13 years, the highest Price to Median PS Value of Diva Laboratories was 1.12. The lowest was 0.89. And the median was 1.08.
ROCO:4153's Price-to-Median-PS-Value is ranked worse than 51.14% of 88
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.885
vs ROCO:4153: 0.89
Diva Laboratories (ROCO:4153) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Diva Laboratories's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
31.40
/
34.96
=
0.90
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diva Laboratories Median PS Value Related Terms
Diva Laboratories Median PS Value Historical Data
* Premium members only.
The historical data trend for Diva Laboratories's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4153 vs TMO, DHR, IDXX: Median PS Value Comparison
For the Diagnostics & Research subindustry, Diva Laboratories's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diva Laboratories Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Diva Laboratories's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 2.3716.
Diva Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$14.741.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diva Laboratories (ROCO:4153) has a Median PS Value of NT$34.96 as of Jul. 15, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Diva Laboratories and its competitors. This is 3137% above median its historical median of 1.08. Over the past decade, Diva Laboratories' Median PS Value has ranged from 0.89 to 1.12. According to the industry distribution chart, Diva Laboratories ranks #45 out of 88 companies in the Medical Diagnostics & Research industry, placing it in the top 51.1%.
Is Diva Laboratories' Median PS Value too high?
Diva Laboratories' current Median PS Value of NT$34.96 is 3137% above median its 10-year median of 1.08. Over the past 10 years, this metric has ranged from a low of 0.89 to a high of 1.12. Based on the distribution chart, Diva Laboratories ranks #45 out of 88 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Diva Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diva Laboratories' Median PS Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diva Laboratories ranks #45 out of 88 companies for Median PS Value. This places Diva Laboratories in the lower half of its industry. The industry median Median PS Value is 0.89. Historically, Diva Laboratories' own Median PS Value has ranged from 0.89 to 1.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.89, based on 88 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Diva Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diva Laboratories's current Median PS Value is NT$34.96, which is 3137% above median its own 10-year median of 1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diva Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Diva Laboratories (ROCO:4153) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.03, compared to a current price of NT$31.40 — trading 17.4% below its estimated fair value. The current Median PS Value is NT$34.96, which is 3137% above median its 10-year median of 1.08. Diva Laboratories' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Diva Laboratories (ROCO:4153), the current Median PS Value is NT$34.96 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diva Laboratories (ROCO:4153) Overvalued in 2026?
Based on GuruFocus' analysis, Diva Laboratories stock appears to be undervalued.
The current stock price of NT$31.40 is trading 17.4% below its estimated GF Value™ of NT$38.03.
GuruFocus considers Diva Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4153:
Median PS Value: NT$34.96 (3137% above median its 10-year median of 1.08)
GF Value™: NT$38.03 vs. price of NT$31.40 (17.4% below fair value)
No single metric tells the full story. See the ROCO:4153 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diva Laboratories Ltd is engaged in the sale, manufacturing and development of medical equipment and computer-related devices. Its products are divided into Medical display which includes radiology, endo/surgical, touch, and embedded display; and Industrial display which includes touch display monitors. It derives revenue from sale of Medical monitors, Medical parts, Industrial monitors, Industrial parts, and Parts. Geographically it operates and derives revenue from Taiwan.
74GF Score
Get the complete analysis for ROCO:4153
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4153 has been successfully added to your 
